On December 16, 2024, Fujian Guangshengtang Pharmaceutical Co., Ltd. announced that its innovative hepatitis B treatment drug, Neracorvir (Nerecovir), was added to the Breakthrough Therapy List. This designation is expected to accelerate the drug's development, recognizing its significant clinical advantages and novel antiviral mechanism.
Nerecovir is a new type of hepatitis B core protein or nucleocapsid modulator, belonging to a new class of anti-hepatitis B virus drugs under development. It has shown a good safety profile and significant efficacy in patients with chronic hepatitis B hypoviremia, with a further significant inhibitory effect on hepatitis B virus DNA on the basis of nucleoside drug therapy.
The drug has obtained a study summary report for the Phase II clinical trial in September 2024, showing promising results. Nerecovir is considered a potential first-in-class innovative drug globally, expected to promote new progress in hepatitis B treatment.
Guangshengtang is committed to creating innovative drugs and contributing to the R&D, innovation, and development of independent and controllable drugs in China. The company has a comprehensive layout of liver health product lines and is actively expanding products in cardiovascular and men's health fields.
In addition to Guangshengtang, several other companies, including Xiangxue Pharmaceutical, Mabwell, and Hengrui Pharmaceutical, have also had their drugs included in the Breakthrough Therapy List, highlighting the ongoing advancements in medical treatments and the pharmaceutical industry's commitment to innovation.
